A dvances in the treatment of osteoporosis are demonstrated by the substantial antifracture efficacy of bisphosphonates. 1 However, the effectiveness of these therapies is often compromised by suboptimal patient compliance, leading to increased risk of fracture, medical costs, and hospitalizations. 2 Taiwan is currently witnessing an increasing trend in osteoporosis with age, with the mean prevalence in men and women aged 50 years or older being 1.63% and 11.35%, respectively. 3 Of further concern are the increasing refracture rates and decreasing rates of compliance with the progress of treatment for osteoporosis, demonstrated in a nationwide study. 4 Soong et al 4 included data from 56,036 Taiwanese patients with osteoporosis who received treatment with a commonly used bisphosphonate agent, alendronate, with 10-mg daily or 70-mg weekly dosing. The compliance rate in the study dropped rapidly from 87.6% at 30 days to 61.8% at 60 days, to as low as 28.2% at 1 year. Of patients who experienced refractures, most (72.5%) were less than 80% compliant; in addition, older patients were at higher risk of refracture. 4 Similarly, another study reported a compliance rate of 38% among Taiwanese patients with osteoporosis and hip fractures. During the first year of treatment, the risk of refracture of compliant patients
The effectiveness of current treatments for osteoporosis is limited by poor patient compliance. However, a favorable dosing regimen of zoledronic acid (ZA) has the potential to improve patient compliance and thus clinical outcomes. The author conducted a retrospective analysis to examine adherence to and the antiosteoporotic effects of a once-yearly infusion of 5 mg of ZA in Taiwanese patients with osteoporosis for up to 48 months. Five men and 149 postmenopausal women (mean age, 77.1 years) were included. Prior to ZA treatment, 66.2% of patients had fractures; most patients discontinued previous treatments due to compliance or convenience issues. Approximately 85% of patients received at least 2 infusions of ZA. Following ZA treatment, bone mineral density improved from baseline at 12 months (11% from baseline; P=.01) and 48 months (20.7% from baseline; P=.009). In addition there was a significant reduction in mean beta-C-telopeptide at all time points from 12 (P<.001) to 36 months (P=.010). New clinical fractures occurred in 16 (10.4%) patients, of which 12 patients experienced a single fracture. Zoledronic acid had an acceptable safety profile; no adverse events were considered to be drug related. Treatment with ZA improved bone health by enhancing bone mineral density and reducing bone turnover, even in high-risk patients. Low fracture rates and high adherence further elucidate the benefits of ZA in the treatment of osteoporosis. [Orthopedics. 2016; 39(2):e263-e270.] was 70% lower than that for noncompliant patients. 5 Therefore, there exists a dire need to incorporate new antiosteoporotic agents with convenient dosing regimens for use, particularly in Taiwan.
The advent of new-generation bisphosphonates such as zoledronic acid (ZA) with a prolonged dosing interval has the potential to improve patient compliance and thus clinical outcomes. The onceyearly infusion of 5 mg of ZA is approved by the US Food and Drug Administration for the treatment of osteoporosis in men and postmenopausal women. 6, 7 A metaanalysis including 9 randomized, controlled trials (RCTs) on the use of ZA in patients with osteoporosis demonstrated a 2.98-fold increase in bone mineral density (BMD) compared with placebo, together with a decrease in the rate of fractures by 32% over time. 8 Zoledronic acid has shown comparable efficacy with other first-line bisphosphonates such as alendronate and risedronate. 9, 10 It is known to have high binding affinity for bone mineral and exerts its antiresorptive action by inhibition of farnesyl pyrophosphate synthase enzyme. 1 Additional benefit stems from the once-yearly dosing regimen of ZA, preferred by most patients over weekly oral therapy. 11 The benefits of ZA have been described in extant literature, including pivotal trials 7, 12, 13 ; however, it is important to evaluate whether these protective effects persist in patients for a longer duration, specifically in everyday practice settings. Although RCTs are the gold standard for determining a drug's efficacy and safety, many patients with osteoporosis are not included in RCTs because of comorbidities and their use of prior therapies. 7, 12 Therefore, the current author performed a retrospective analysis of clinical data from all patients with and without osteoporotic fractures treated with ZA at a hospital in Taiwan. Selection of patients regardless of comorbidities or medical history allowed unbiased assessment in real-world clinical settings. In particular, the author examined whether the effectiveness, safety, and antifracture effect of ZA therapy were sustained until 48 months. To the author's knowledge, this is the first study in Taiwan to assess the long-term effects of ZA in patients with osteoporosis.
Materials and Methods

Study Design
This retrospective, single-center, noninterventional study examined the effectiveness and safety of once-yearly intravenous infusion of 5 mg/100 mL of ZA (Aclasta; Novartis Pharmaceuticals Corporation, Basel, Switzerland) in patients with osteoporosis. The study was conducted with a protocol approved by the institutional review board and in accordance with the Good Clinical Practice (GCP) guidelines and the principles of the Declaration of Helsinki. Relevant anonymized patient data were collected from medical charts obtained from St Martin De Porres Hospital, Chia-Yi City, Taiwan.
Patients
In total, 154 adult patients with osteoporosis who had received a once-yearly 5-mg dose of ZA intravenously between January 2008 and December 2011 were included. Patients with hypersensitivity to ZA or any bisphosphonates, hypocalcemia, renal impairment with creatinine clearance less than 35 mL/minute, or uveitis, as well as pregnant/breastfeeding women, were excluded.
Endpoints
The primary efficacy endpoint was the percentage change in BMD from baseline after 12 months of ZA treatment. The secondary efficacy endpoints were the percentage change in BMD from baseline after 12, 24, 36, and 48 months of ZA treatment; the incidence rate of clinical fracture; the change in beta-Ctelopeptide (ß-CTX) from baseline at 12, 24, 36, and 48 months after the infusion of ZA; and the relationship between pretreated ß-CTX and the change in BMD.
The exploratory endpoints were adherence to therapy, treatment patterns under real-world clinical practice (including treatment prescribed, reasons for switching to ZA, and reasons for treatment discontinuation), and potential risk factors. Safety endpoints comprised incidence of adverse events and acute-phase reactions.
Outcome Measures
Bone mineral density was measured at the spine and hip for each patient, and the poorest BMD T-score (spine or hip) at a given time point was considered for further analysis. Before ZA administration, serum calcium, creatinine, and ß-CTX levels were examined, and the drug was infused only if normal levels of calcium and creatinine were present. The assessment of clinical fracture was done in the author's clinic if a patient experienced acute or chronic back pain or progressive pitch-forward posture. Patients were followed up every year, and their radiographs were compared with those from the previous assessment. All new fractures were recorded in their medical chart.
The efficacy of treatment was evaluated by measuring change from baseline BMD at 12, 24, 36, and 48 months; change from baseline ß-CTX; relationship between pretreated ß-CTX and change in BMD; and incidence rate of clinical fracture. To evaluate the safety profile of ZA, all documented adverse effects and acute-phase reactions were obtained. Acute-phase reactions occurring within 3 days after an infusion of ZA were considered. Because of concerns over renal safety associated with ZA, 13, 14 renal function was evaluated.
Statistical Analysis
The sample size of this study was calculated based on the primary efficacy variable: percentage change in total hip BMD from baseline. In patients receiving ZA, the total hip BMD is known to increase by approximately 2.8% at 12 months. Using a paired t test with 80% power and a significance level of .05 to detect mean change in total hip BMD of 2.3±8% from baseline, it was determined that a total of 97 patients were required to be included in the study for statistical power.
The baseline characteristics of patients were summarized using descriptive statistics. Paired t tests were used to evaluate the change in BMD and ß-CTX from baseline. For assessment of compliance, adherence to follow-up at the outpatient department and treatment with ZA on a yearly basis were recorded from medical charts.
Incidence rates for adverse events and acute-phase reactions were tested by Fisher's exact test when an unexpected occurrence was observed. Statistical significance was determined by P value less than .05. All statistical analyses were performed with SAS version 9.3 for Windows (SAS Institute, Cary, North Carolina).
results
Baseline Characteristics
The study cohort comprised 149 women and 5 men with a mean age of 77.1 years, mean body weight of 54.6 kg, and mean body mass index of 23.8 kg/m 2 ( Table 1) . The patients were clinically diagnosed with postmenopausal osteoporosis (96.8%) or male osteoporosis (3.2%). One hundred two (66.2%) patients had fractures prior to the initiation of ZA treatment: 74 (72.5%) vertebral, 15 (14.7%) hip, and 13 (12.7%) other. All but 3 patients received surgical intervention. Vertebral fractures underwent vertebroplasty or fusion surgery (Figures 1-2) . Hip fractures underwent hemiarthroplasty or internal fixation. All patients with fractures at baseline were diagnosed with severe osteoporosis with a high risk of recurrent fracture.
Drug Exposure
Mean ZA infusion was 2.6±1.1 doses. Overall, 36.4% of patients received 2 infusions, followed by 31.2%, 15.6%, and 11.7% who received 3, 1, and 4 infusions, respectively. Only 1 patient received 6 infusions of ZA. Mean duration of ZA exposure was 29.5±15.5 months. Drug discontinuation rate was 49.4% (76 of 154) within the study period. Drug
B Figure 2:
A 57-year-old female patient had esophageal cancer and underwent surgery and chemotherapy 10 years ago. She reported severe upper back pain when bending her back. A T7 fracture was diagnosed, and vertebral augmentation surgery was performed. One month later, she felt incapacitating lower back pain when she fell. An L2 burst fracture was diagnosed, and an anterior corpectomy with fusion surgery was performed, but 2 weeks later, she developed a stress fracture at L1 when she fell down the stairs at home. Posterior instrumentation and fusion surgery with preventive vertebroplasty were performed. Bone mineral density at baseline was -3.74. She received 2 zoledronic acid injections, and bone mineral density increased to -3.19. Thoracic plain anteroposterior (left) and lateral (right) radiographs when she was sent to the emergency department (A). T2-weighted cervical thoracic spine (left) and thoracolumbar spine (right) magnetic resonance imaging revealed a T7 fracture 
Drug Use
Of the patients enrolled in the study, 76 (49.4%) discontinued treatment with ZA due to undocumented causes (26.3%), lack of sufficient response (25.0%), compliance issues (23.7%), being cured (BMD >1.5) (18.4%), or convenience issues (6.6%). Concomitant medication use, along with or after infusion of ZA, was common and included nonsteroidal antiinflammatory drugs (NSAIDs; 92.2%), histamine H 2 antagonists (90.3%), and alkalinizing agents (0.6%). All patients were given daily supplements of 15 mL of All-right Calcium suspension (Standard Chem & Pharm Co, Ltd, Sinying City, Taiwan); 1 mL contains 103 mg tricalcium phosphate + 1600 IU vitamin A + vitamin D3 (160 IU cholecalciferol).
Seventy (45.5%) patients had undergone prior treatment for osteoporosis, with the most common medications being calcitonin (26.6%), oral bisphosphonates (18.2%), and selective estrogen therapy (14.3%; Table 2 ). Most patients discontinued their previous treatments due to compliance or convenience issues ( Table 3) .
Bone Mineral Density
Mean baseline BMD T-scores were -2.8±0.8 for the lumbar spine and -2.4±0.8 for the hip. At month 12, there was a significant improvement from baseline (primary endpoint) in lumbar spine T-score by 0.2±0.7 (11.0%) (P=.01). Total hip T-score at 12 months was comparable to that at baseline. Subsequently, at 24 and 36 months, lumbar T-scores were maintained; however, there was a significant increase by 0.7±0.7 (20.7%) at 48 months (P=.009; Table 4 ).
Beta-C-Telopeptide
At baseline, a total of 142 patients had a mean ß-CTX of 0.4±0.3 ng/mL. A significant decrease was observed at 12 months, yielding a reduction of 0.2±0.3 ng/mL (P<.001). Similar reductions were observed at 24 months (0.1±0.3 ng/mL; P<.001) and 36 months (0.1±0.2 ng/mL; P=.010), as was a nonsignificant effect at 48 months (0.1±0.3 ng/mL; P=.304). There was no significant correlation between BMD T-scores and level of ß-CTX at any time point except at 48 months, when a significant moderately positive correlation was observed (P=.037; r=0.661); however, this was not found to be meaningful because only a few patients were included in this analysis.
Clinical Fractures
New clinical fractures during treatment with ZA occurred in 16 (10.4%) patients; 12 patients (75%) had 1 fracture and 4 (25%) patients had 2 fractures. All fractures occurred due to trauma, either a fall or a traffic accident. Of the fractures recorded, 9 were vertebral, 6 were nonvertebral, and 1 was a hip fracture. Overall, the mean number of fractures per patient was 1.6±1.3, with 2.0±1.6 vertebral, 1.0±0.0 nonvertebral, and 1.0±0.0 hip fractures.
Safety
During the treatment period, 52 adverse events were reported from 36 (23.4%) patients ( Table 5 ). Of these, 11 were considered serious adverse events and occurred in 9 (5.8%) patients. However, none of the adverse events or serious adverse events were considered drug related. Among serious adverse events dur- Table 3 Reasons for Discontinuation of Previous Treatments n Feature Article ing the treatment period, infections of the urinary tract, bronchitis, bone compressions at the lumbar spine and thoracic vertebrae, fever with sepsis, and colon cancer were reported. All serious adverse events resulted in hospitalization; however, none were fatal. Only 20 (13.0%) patients experienced acute-phase reactions, which were of mild to moderate intensity and resolved within 3 days of onset.
Laboratory Outcomes
Mean levels of serum calcium and creatinine and the creatinine clearance rate were reported to be 9.1 mg/dL, 0.8 mg/dL, and 69.1 mL/min, respectively, and were within normal limits.
discussion
This study demonstrated improvement in lumbar spine BMD at 12 and 48 months (20.7% from baseline), along with maintenance of total hip BMD throughout the treatment period, after once-yearly treatment with ZA in a real-world, hospitalbased setting. This corroborates the findings of previous RCTs on ZA. 7, 12, 13 Similar to previous reports, 7,13 the increment in BMD was accompanied by a reduction in the bone turnover marker ß-CTX at all time points until 48 months. No correlation was observed between BMD and ß-CTX at 12 months and at most of the later time points, and a plausible reason for the lack of this effect was not identified. Nevertheless, an improvement in BMD and a reduction in ß-CTX were observed independently at 48 months in naïve patients, as well as those who received prior treatments. Overall, the results of the current study highlight the long-term success of ZA therapy in real-life settings in Taiwanese patients with osteoporosis.
Of patients in this study, 72.5% with vertebral fractures and 14.7% with hip fractures received surgical management. These patients were temporarily disabled and were at high risk for recurrent fracture, but consistent with previous speculations regarding reduced risk of fractures after ZA therapy, 13 this study demonstrated that new clinical fractures occurred in only 10.4% of patients, and most of these (75%) were single-site fractures. This is much lower than the refracture incidence observed in a previous study that reported a refracture rate of more than 20%. 15, 16 n Feature Article
Another study reported that treatment with oral bisphosphonates led to the composite outcome of death or fracture in 20% of patients with previous fractures. 17 The current study shows that ZA therapy was able to curb the fracture rates in patients with severe osteoporosis who were at high risk of recurrent fractures at baseline. The better clinical outcomes in this study are due to improvement of bone quality, which is reflected in higher BMD increase in this study (11.0% at 12 months, 20.7% at 48 months) than in other studies. 8, 10 The study cohort comprised an older population (mean age, 77.1 years) with a low BMD value, and 14 (18.4%) patients were cured (BMD >1.5) after injection of ZA. The small sample size and unique patient population may explain the superior clinical outcome.
Compliance was the main reason for discontinuing previous medications, and, thus, the benefits of treatment would not have been seen. Nonadherence to the treatment, known to compromise efforts toward reducing the occurrence of new fractures in patients with osteoporosis, 18 was overcome by the convenient dosing regimen of ZA. Solomon et al 19 reported that, within 1 year of initiating treatment for osteoporosis, nearly 45% of patients discontinued their medications, especially elderly patients. In the current study, approximately 85% of patients received at least 2 infusions of ZA, and 15.6% received only 1 injection (84.4% compliance of first year), with an exposure duration of 29.5 months (50.6% compliance during 28 months), suggesting a prolonged treatment duration of more than 2 years. The better adherence found in the current study could be attributed to the less-frequent dosing schedule (once yearly) of ZA and its favorable effectiveness and safety profile, making it ideal for long-term treatment. These benefits could be tied to the cost-effectiveness of ZA regardless of fracture type, especially when patient compliance is considered, as exemplified in European studies. 20, 21 Common adverse events observed with oral bisphosphonate therapy, such as those affecting the upper gastrointestinal tract, 22 are rare with intravenous ZA. The current study demonstrated a favorable safety profile of ZA and, unlike other bisphosphonates such as risedronate and alendronate, 22, 23 none of the adverse events or serious adverse events were suspected to be related to the drug. In addition, there were no reports of hypocalcemia, osteonecrosis of the jaw, or atypical fractures during the study period, even in a patient who received 6 years of ZA treatment. This study's findings are further supported by the HORIZON extension study, which reported no such complications during the 9-year study period with ZA. 24 Acute-phase reactions, often present after the first infusion of ZA, are known to reflect the development of widespread inflammatory changes. 25, 26 Twenty patients experienced mild to moderate acute-phase reactions in the current study, all of which resolved within 3 days of onset. The proportion of patients who experienced acute-phase reactions (13%) was much lower than previously reported in the pivotal HORIZON trial (42.4%). 13 The author believes the low rates of acutephase reactions are attributable to the standard operating procedures followed in the study. Patients were directed to take NSAIDs and 200 mL of water prior to ZA infusion with an injection time of at least 30 minutes. Patients took at least 1000 mL of water on the first day after the injection. At the onset of an acute-phase reaction, NSAIDs were administered again until the reaction subsided. Acute-phase reactions were not observed for most patients during the second injection. Nevertheless, consistent with the current study, the most frequent acute-phase reactions reported previously were fever, myalgia, and arthralgia. 13, 27 Although acute-phase reactions do not deter adherence to treatment, patient education about the possible occurrence of these events is necessary.
The main strengths of this study were the inclusion of a diverse group of patients in real-world settings, the assessment of multiple outcomes, and a long follow-up period. Nevertheless, due to limitations in retrieving medical records, some patient data, such as reasons for discontinuing the treatment, were not available and could not be included in analysis. Despite this, the study provides valuable insights into the use of ZA in real-world settings.
conclusion
This study showed that treatment with once-yearly dosing of ZA improves adherence and clinical outcomes in patients with osteoporosis. The treatment was effective in preventing refracture in patients with osteoporotic fractures by improving bone health through increasing BMD and decreasing the level of bone turnover markers. Zoledronic acid was also associated with an acceptable safety profile, with no adverse events or serious adverse events related to the drug.
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